Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Primary Inclusion Criteria: * Relapsed or refractory histologically or cytologically confirmed Stage IIIB, IV, or recurrent NSCLC * Previously treated and failed to respond to standard therapy or progressed after standard therapy * 18 years of age or older Primary Exclusion Criteria: * Received a non-FDA approved investigational agent within the last 4 weeks. * Previous cancer therapies (chemotherapy, hormonal therapy, monoclonal antibodies or radiation therapy) within the last 3 weeks, 8 weeks for fully human or humanized monoclonal antibodies * Infection requiring antibiotics or hospitalization within the last 2 weeks * HIV, Hepatitis-B, Hepatitis-C * Pregnant or breast-feeding women * Major surgery within the last 4 weeks * History of other cancers within the past 5 years